C3aR and C5aR Modulate T-cell Responses in the MRL Mouse

C3aR 和 C5aR 调节 MRL 小鼠的 T 细胞反应

基本信息

项目摘要

DESCRIPTION (provided by applicant): Systemic Lupus Erythematosus (SLE) is a heterogeneous disorder characterized by autoimmunity and the development of progressive immune complex renal disease. The pathogenesis of SLE is complex and multi- factorial; substantial clinical and experimental data supports roles for auto-antibodies, immune complexes, apoptosis, and effector T-cells in the development of SLE. Disturbances in the complement system are strongly associated with the development and progression of many forms of SLE particularly lupus nephrits. Complement activation results in the production of anaphylatoxins, C3a and C5a, which signal through ubiquitously expressed G-protein coupled receptors (C3aR and C5aR). Signaling via the C3aR and C5aR has historically thought to function to active innate immune responses. The studies contained in this proposal are designed to define and characterize the ability of C3aR and C5aR to alter adaptive immune responses in a biologically relevant complement dependent model of human disease, namely the MRL/lpr mouse model of lupus nephritis. Mice with targeted deletions of C3aR and C5aR as well as mice deficient in both the C3aR and the C5aR have been back-crossed 9 generations on to the MRL/lpr genetic background. Comparative studies of renal injury and immunologic responses including antigent presenting cell function, T-cell, and B-cell function will be performed. Additionally, experiments investigating renal parenchymal responses in terms of cellular proliferation, extra-cellular matrix production, and apoptosis will be performed. These studies are designed to advance our understanding of the mechanisms by which complement activation products modulate cellular immune responses and renal parenchymal responses in immune mediated renal injury.
描述(由申请人提供):系统性红斑狼疮(SLE)是一种异质性疾病,其特征是自身免疫和进行性免疫复合物肾病的发展。SLE的发病机制是复杂和多因素的;大量的临床和实验数据支持自身抗体、免疫复合物、细胞凋亡和效应T细胞在SLE发展中的作用。补体系统的紊乱与许多形式的SLE特别是狼疮性肾炎的发生和进展密切相关。补体激活导致过敏毒素C3 a和C5 a的产生,其通过普遍表达的G蛋白偶联受体(C3 aR和C5 aR)发出信号。通过C3 aR和C5 aR的信号传导在历史上被认为对主动先天免疫应答起作用。本提案中包含的研究旨在定义和表征C3 aR和C5 aR改变人类疾病的生物学相关补体依赖性模型(即狼疮肾炎的MRL/lpr小鼠模型)中适应性免疫应答的能力。具有C3 aR和C5 aR靶向缺失的小鼠以及C3 aR和C5 aR两者缺陷的小鼠已经在MRL/lpr遗传背景上回交9代。将进行肾损伤和免疫应答的比较研究,包括抗原呈递细胞功能、T细胞和B细胞功能。此外,还将进行实验,研究肾实质在细胞增殖、细胞外基质产生和细胞凋亡方面的反应。这些研究旨在促进我们对补体激活产物调节免疫介导的肾损伤中的细胞免疫应答和肾实质应答的机制的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL C BRAUN其他文献

MICHAEL C BRAUN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL C BRAUN', 18)}}的其他基金

Role of C7 in Resistance to Neisseria Infections
C7 在抵抗奈瑟菌感染中的作用
  • 批准号:
    7962860
  • 财政年份:
    2010
  • 资助金额:
    $ 28.85万
  • 项目类别:
Role of C7 in Resistance to Neisseria Infections
C7 在抵抗奈瑟菌感染中的作用
  • 批准号:
    8134950
  • 财政年份:
    2010
  • 资助金额:
    $ 28.85万
  • 项目类别:
C3aR and C5aR Modulate T-cell Responses in the MRL Mouse
C3aR 和 C5aR 调节 MRL 小鼠的 T 细胞反应
  • 批准号:
    7903765
  • 财政年份:
    2009
  • 资助金额:
    $ 28.85万
  • 项目类别:
C3aR and C5aR Modulate T-cell Responses in the MRL Mouse
C3aR 和 C5aR 调节 MRL 小鼠的 T 细胞反应
  • 批准号:
    8397223
  • 财政年份:
    2006
  • 资助金额:
    $ 28.85万
  • 项目类别:
C3aR and C5aR Modulate T-cell Responses in the MRL Mouse
C3aR 和 C5aR 调节 MRL 小鼠的 T 细胞反应
  • 批准号:
    7368084
  • 财政年份:
    2006
  • 资助金额:
    $ 28.85万
  • 项目类别:
C3aR and C5aR Modulate T-cell Responses in the MRL Mouse
C3aR 和 C5aR 调节 MRL 小鼠的 T 细胞反应
  • 批准号:
    7570091
  • 财政年份:
    2006
  • 资助金额:
    $ 28.85万
  • 项目类别:
C3aR and C5aR Modulate T-cell Responses in the MRL Mouse
C3aR 和 C5aR 调节 MRL 小鼠的 T 细胞反应
  • 批准号:
    7212120
  • 财政年份:
    2006
  • 资助金额:
    $ 28.85万
  • 项目类别:
Urinary Biomarkers in Murine MPGN
小鼠 MPGN 中的尿液生物标志物
  • 批准号:
    7140339
  • 财政年份:
    2005
  • 资助金额:
    $ 28.85万
  • 项目类别:
Urinary Biomarkers in Murine MPGN
小鼠 MPGN 中的尿液生物标志物
  • 批准号:
    6962745
  • 财政年份:
    2005
  • 资助金额:
    $ 28.85万
  • 项目类别:
The Role of C3a and C5a in BEA Induced Nephritis
C3a 和 C5a 在 BEA 诱发肾炎中的作用
  • 批准号:
    6532064
  • 财政年份:
    2002
  • 资助金额:
    $ 28.85万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 28.85万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 28.85万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 28.85万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 28.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 28.85万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 28.85万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 28.85万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 28.85万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 28.85万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 28.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了